This inventor holds 3 USPTO granted patents. Top assignee: Syntex (u.s.a.) Inc.. Active years: 1995-1996.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1995-1996
Title: Paul J Jarosz: Innovator in Pharmaceutical Formulations
Introduction
Paul J Jarosz is a notable inventor based in Los Altos, CA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of high dose formulations. With a total of 3 patents to his name, Jarosz continues to push the boundaries of pharmaceutical innovation.
Latest Patents
Jarosz's latest patents include innovative formulations that enhance the delivery of critical medications. One of his patents focuses on high dose formulations of mycophenolate mofetil and mycophenolic acid. This invention allows for the convenient manufacturing of high dose oral formulations through the hot melt filling of a supercooled liquid into a pharmaceutical dosage form. Another patent addresses high dose ranolazine formulations, similarly utilizing the hot melt filling technique to create effective oral pharmaceutical formulations.
Career Highlights
Throughout his career, Jarosz has been associated with Syntex (U.S.A.) Inc., where he has played a pivotal role in advancing pharmaceutical technologies. His work has not only contributed to the company’s portfolio but has also had a lasting impact on patient care through improved medication delivery systems.
Collaborations
Jarosz has collaborated with esteemed colleagues such as Glenn J Samuels and Charles Lee. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas in the pharmaceutical field.
Conclusion
Paul J Jarosz stands out as a key figure in pharmaceutical innovation, with a focus on high dose formulations that enhance medication efficacy. His contributions continue to shape the future of drug delivery systems, benefiting both the industry and patients alike.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile